Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2461-2471

  Li, Meiying ^a   Yu, Xuejun ^a   Guo, Hui ^a   Sun, Limei ^a   Wang, Aijun ^a   Liu, Qiji ^b   Wang, Xiuwen ^a   Li, Jisheng ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antitumor; Apoptosis; Bufalin; Cell cycle arrest; Hsp27; Pancreatic cancer

Indexed keywords

BUFALIN; CAMPTOTHECIN DERIVATIVE; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; GEMCITABINE; HEAT SHOCK PROTEIN 27; PROCASPASE 3; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CELL CYCLE ARREST; CHINESE MEDICINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PANCREAS CANCER; PRIORITY JOURNAL; SURVIVAL RATE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BUFANOLIDES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84899103439     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1326-6     Document Type: Article

References (51)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-20.
2. Guo X, Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas. 2005;31:13-22.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
4. Duffy JP, Eibl G, Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer. 2003;2:12.
5. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
6. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002;94:902-10.
7. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the gip-1 study. J Clin Oncol. 2010;28:1645-51.
8. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-8.
9. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
10. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-25.
11. Von Hoff D, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, Seay TE, Tjulandin S, Ma WW, Saleh MN: Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT): 2013 ASCO Gastrointestinal Cancers Symposium, Abstract, 2012, 148, pp 24-26
12. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157-88.
13. Xie XB, Yin JQ, Wen LL, Gao ZH, Zou CY, Wang J, et al. Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research. PLoS One. 2012;7:16.
14. Xie CM, Chan WY, Yu S, Zhao J, Cheng CH. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and jnk activation. Free Radic Biol Med. 2011;51:1365-75.
15. Zhu Z, Li E, Liu Y, Gao Y, Sun H, Wang Y, et al. Bufalin induces the apoptosis of acute promyelocytic leukemia cells via the downregulation of survivin expression. Acta Haematol. 2012;128:144-50.
16. Hsiao YP, Yu CS, Yu CC, Yang JS, Chiang JH, Lu CC, et al. Triggering apoptotic death of human malignant melanoma a375.S2 cells by bufalin: involvement of caspase cascade-dependent and independent mitochondrial signaling pathways. Evid Based Complement Alternat Med. 2012;591241:7.
17. Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L, et al. Down-regulation of cbl-b by bufalin results in up-regulation of dr4/dr5 and sensitization of trail-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol. 2012;138:1279-89.
18. Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng Y, et al. Pi3k/akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs. 2009;20:59-64.
19. Yu CH, Kan SF, Pu HF. Jea Chien E, Wang PS: Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci. 2008;99:2467-76.
20. Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21:637-43.
21. Huang WW, Yang JS, Pai SJ, Wu PP, Chang SJ, Chueh FS, et al. Bufalin induces g(0)/g(1) phase arrest through inhibiting the levels of cyclin d, cyclin e, cdk2 and cdk4, and triggers apoptosis via mitochondrial signaling pathway in t24 human bladder cancer cells. Mutat Res. 2012;732:26-33.
22. Zhu Z, Sun H, Ma G, Wang Z, Li E, Liu Y. Bufalin induces lung cancer cell apoptosis via the inhibition of pi3k/akt pathway. Int J Mol Sci. 2012;13:2025-35.
23. Concannon CG, Gorman AM, Samali A. On the role of hsp27 in regulating apoptosis. Apoptosis. 2003;8:61-70.
24. Ischia J, Saad F, Gleave M. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Curr Opin Urol. 2013;23:194-200.
25. Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterbauer A, Hoetzenecker K, et al. Discrimination of clinical stages in non-small cell lung cancer patients by serum hsp27 and hsp70: a multi-institutional case-control study. Clin Chim Acta. 2012;413:1115-20.
26. Kapranos N, Kominea A, Konstantinopoulos PA, Savva S, Artelaris S, Vandoros G, et al. Expression of the 27-kda heat shock protein (hsp27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol. 2002;128:426-32.
27. Olejek A, Damasiewicz-Bodzek A, Bodzek P, Wielkoszynski T, Zamlynski J, Stoltny P, et al. Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma. Int J Gynecol Cancer. 2009;19:1516-20.
28. Yang L, Cao L, Yang M, Tang D, Kang R, Min X, et al. Hsp27: A novel therapeutic target for pediatric m4/m5 acute myeloid leukemia. Oncol Rep. 2013;29:1459-66.
29. Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, et al. Protein profiling of microdissected pancreas carcinoma and identification of hsp27 as a potential serum marker. Clin Chem. 2007;53:629-35.
30. Schafer C, Seeliger H, Bader DC, Assmann G, Buchner D, Guo Y, et al. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2012;16:1776-91.
31. Liu QH, Zhao CY, Zhang J, Chen Y, Gao L, Ni CY, et al. Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: comparative proteomic analyses. Mol Med Rep. 2012;6:767-73.
32. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Taba K, Fujimoto M, Okita K, et al. A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Rep. 2008;1:429-34.
33. Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Mori-Iwamoto S, et al. Knk437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Chemotherapy. 2011;57:12-6.
34. Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, et al. Ogx-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2011;20:104.
35. Mori-Iwamoto S, Taba K, Kuramitsu Y, Ryozawa S, Tanaka T, Maehara S, et al. Interferon-gamma down-regulates heat shock protein 27 of pancreatic cancer cells and helps in the cytotoxic effect of gemcitabine. Pancreas. 2009;38(2):224-6. doi: 10.1097/MPA.0b013e3181773970.
36. Zhang X, Liu Z, Xu B, Sun Z, Gong Y, Shao C. Neferine, an alkaloid ingredient in lotus seed embryo, inhibits proliferation of human osteosarcoma cells by promoting p38 mapk-mediated p21 stabilization. Eur J Pharmacol. 2012;677:47-54.
37. Jiang Y, Zhang Y, Luan J, Duan H, Zhang F, Yagasaki K, et al. Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology. 2010;62:573-83.
38. Zhu Z, Li E, Liu Y, Gao Y, Sun H, Ma G, et al. Inhibition of jak-stat3 pathway enhances bufalin-induced apoptosis in colon cancer sw620 cells. World J Surg Oncol. 2012;10:1477-7819.
39. Hong SH, Choi YH. Bufalin induces apoptosis through activation of both the intrinsic and extrinsic pathways in human bladder cancer cells. Oncol Rep. 2012;27:114-20.
40. Qi F, Inagaki Y, Gao B, Cui X, Xu H, Kokudo N, et al. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via fas- and mitochondria-mediated pathways. Cancer Sci. 2011;102:951-8.
41. Xie CM, Liu XY, Yu S, Cheng CH. Cardiac glycosides block cancer growth through hif-1alpha- and nf-kappab-mediated plk1. Carcinogenesis. 2013;34:1870-80.
42. Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G. Hsp27 and hsp70: potentially oncogenic apoptosis inhibitors. Cell Cycle. 2003;2:579-84.
43. Pandey P, Farber R, Nakazawa A, Kumar S, Bharti A, Nalin C, et al. Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene. 2000;19:1975-81.
44. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP, Solary E. Hsp27 inhibits cytochrome c-dependent activation of procaspase-9. Faseb J. 1999;13:2061-70.
45. Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, et al. Heat shock protein 27 controls apoptosis by regulating akt activation. J Biol Chem. 2003;278:27828-35.
46. Guo K, Kang NX, Li Y, Sun L, Gan L, Cui FJ, et al. Regulation of hsp27 on nf-kappab pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis. BMC cancer. 2009;9:1471-2407.
47. Hardwick JM, Soane L. Multiple functions of bcl-2 family proteins. Cold Spring Harb Perspect Biol. 2013;5(2). doi: 10.1101/cshperspect.a008722.
48. Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci U S A. 1997;94(7):2776-8.
49. Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the s and g2 checkpoint to treat cancer. Drug Discov Today. 2012;17:194-202.
50. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 2008;98:523-8.
51. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316-23.